Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The prevention of atrial fibrillation related thromboembolism in the dialysis population is
unclear. While the practice of anticoagulation appears favorable in patients with
mild-to-moderate chronic kidney disease, no patients with severe chronic kidney disease
(estimated glomerular filtration rate <25 ml/min), and specifically those receiving dialysis,
have been included in randomized trials.Moreover, the effect of anticoagulation in the
dialysis population may fundamentally differ from those studied in clinical trials.
Accordingly, characterization of the optimal management strategy to reduce the risk of stroke
and systemic embolism in patients with atrial fibrillation receiving dialysis is a priority.
The overall goal of this pilot trial is to evaluate the feasibility of conducting a
randomized controlled trial comparing anticoagulation strategies in patients with atrial
fibrillation receiving dialysis (either hemodialysis or peritoneal dialysis).
Phase:
Phase 2
Details
Lead Sponsor:
St. Michael's Hospital, Toronto Unity Health Toronto
Collaborators:
Canadian Institutes of Health Research (CIHR) The George Institute for Global Health (Sydney, Australia)